Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1143-1150

  Garcia Donas, Jesus ^a   Esteban, Emilio ^b   Leandro García, Luis Javier ^c   Castellano, Daniel E ^e   del Alba, Aranzazu González ^f   Climent, Miguel Angel ^g   Arranz, José Angel ^h   Gallardo, Enrique ⁱ   Puente, Javier ^j   Bellmunt, Joaquim ^k   Mellado, Begoña ^l   Martínez, Esther ^m   Moreno, Fernando ⁿ   Font, Albert ^o   Robledo, Mercedes ^c,d   Rodríguez Antona, Cristina ^c,d  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Centro Nacional de Investigations Oncológicas   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ Servicio de Cirugía General Y Aparato Digestivo   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k HOSPITAL DEL MAR   (Spain)

^l HOSPITAL CLÍNIC   (Spain)

^m Hosp Univ Ciudad de Jaén   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^o HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; INTERLEUKIN 8; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ADVANCED CANCER; ARTICLE; ASTHENIA; CANCER PATIENT; CLEAR CELL CARCINOMA; DIARRHEA; DNA POLYMORPHISM; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GENETIC MARKER; HAND FOOT SYNDROME; HAZARD RATIO; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPENIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; UNIVARIATE ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CYTOCHROME P-450 CYP3A; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INDIVIDUALIZED MEDICINE; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT SELECTION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRROLES; RISK ASSESSMENT; RISK FACTORS; SPAIN; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 81255160848     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70266-2     Document Type: Article

References (30)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
3. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-763.
4. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371.
5. Rini BI, Atkins MB Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009, 10:992-1000.
6. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
7. Faivre S, Demetri G, Sargent W, Raymond E Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745.
8. Xu CF, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011, 29:2557-2564.
9. Schneider BP, Radovich M, Miller KD The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009, 15:5297-5302.
10. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010, 117:109-116.
11. Adams VR, Leggas M Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007, 29:1338-1353.
12. Shukla S, Robey RW, Bates SE, Ambudkar SV Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009, 37:359-365.
13. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
14. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005, 338:299-305.
15. Mizuno T, Terada T, Kamba T, et al. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol 2010, 21:1382-1383.
16. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007, 7:154-179.
17. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
18. van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009, 27:4406-4412.
19. van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2010, 17:620-629.
20. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995, 92:3566-3570.
21. Smith NR, Baker D, James NH, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010, 16:3548-3561.
22. Wang Y, Nakayama M, Pitulescu ME, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465:483-486.
23. Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006, 66:2650-2657.
24. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.
25. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007, 5:32.
26. Tvorogov D, Anisimov A, Zheng W, et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010, 18:630-640.
27. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002, 30:883-891.
28. Tomita Y, Shinohara N, Yuasa T, et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2010, 40:1166-1172.
29. Yoo C, Kim JE, Lee JL, et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 2010, 40:980-985.
30. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.